AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Sep 16, 2020

Voting for the 2020 AbbVie CF Scholarship Thriving Student Awards is Open to the Public Until September 30

NORTH CHICAGO, Ill., Sept. 16, 2020 /PRNewswire/ -- AbbVie today announced the start of its annual public voting period for the 2020 Thriving Undergraduate and Thriving Graduate Scholarship. Following this voting period, scholarships totaling $25,000 each will be given to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.

Sep 16, 2020

Malin Akerman Joins CoolSculpting® and CoolTone™ as U.S. Ambassador for the Allergan Aesthetics Body Contouring Portfolio

IRVINE, Calif., Sept. 16, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the partnership between actress and producer Malin Akerman and the Allergan Aesthetics body contouring portfolio. Akerman is named the first Allergan Aesthetics body contouring partner in support of both CoolSculpting®, the #1 nonsurgical fat reduction treatment used most by doctors, and CoolTone™, the latest treatment in the portfolio used to strengthen, tone, and firm the abdomen, buttocks, and thigh muscles.

Sep 14, 2020

Allergan Aesthetics and Skinbetter Science Announce The DREAM Initiative™ To Advance Health Equity and Diversity in Aesthetics

IRVINE, Calif. and PHOENIX, Sept. 14, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and Skinbetter Science® announced the launch of a new long-term, educational initiative – DREAM: Driving Racial Equity in Aesthetic Medicine.  The DREAM Initiative is committed to furthering the principles of racial and ethnic diversity, inclusion, respect and understanding in the fields of dermatology and plastic surgery. 

Sep 11, 2020

AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®

NORTH CHICAGO, Ill., Sept. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present results from several studies, including the DYSCOVER study evaluating the efficacy of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia in patients with advanced Parkinson's disease (PD), at the 2020 International Congress of Parkinson's Disease and Movement Disorders® Virtual Congress, September 12-16. In total, 18 abstracts will be presented, including an overview of the pivotal Phase 3 study design for the investigational medicine ABBV-951 in patients with advanced PD, several studies evaluating the economic burden of PD, as well new and updated data evaluating AbbVie's neuroscience portfolio and pipeline.

Sep 11, 2020

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept. 11, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. 

Sep 04, 2020

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

NORTH CHICAGO, Ill., and SHANGHAI, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies. 

Sep 03, 2020

AbbVie to Present at the Morgan Stanley Healthcare Conference

NORTH CHICAGO, Ill., Sept. 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020.  Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.

Aug 31, 2020

'Say No to Chronic Migraine Monday' Urges People Living with Chronic Migraine to Seek Help from a Headache Specialist

NORTH CHICAGO, Ill., Aug. 31, 2020 /PRNewswire/ -- Healthy living blogger Becca Ludlum knows all too well the physical and mental toll Chronic Migraine can have. She experienced self-described 'daily unbreaking migraine attacks.' Her story is more common than you think. In the U.S., more than 3.3 million adults live with Chronic Migraine1, and people who experience the burden and disability of migraine disease wait on average four years before speaking with a healthcare professional.2 The campaign 'Say No to Chronic Migraine Monday' urges people living with Chronic Migraine to make an appointment today with a headache specialist to discuss treatment options.

Aug 25, 2020

AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis

NORTH CHICAGO, Ill., Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis. AbbVie also submitted an application to the European Medicines Agency (EMA) for RINVOQ earlier this year for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.

Aug 25, 2020

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Harvard University today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.